BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced the presentation of two abstracts detailing positive data for its novel, small molecule ErbB family inhibitor, ARRY-543. The abstracts, which were presented at the American Association for Cancer Research (AACR) 100th Annual Meeting, showed both the clinical benefit of ARRY-543 in tumors that signal through multiple ErbB family members, as well as its efficacy in preclinical models when compared to, and combined with, Herceptin® (trastuzumab), Xeloda® (capecitabine) and Taxotere® (docetaxel) – widely used treatments for solid tumors. ARRY-543 is an oral, potent tyrosine kinase inhibitor of EGFR, ErbB2, and ErbB4, with a resulting impact on ErbB3, and is active in a wide range of human tumor cell lines. The complete posters are available as PDFs on Array’s website at www.arraybiopharma.com.
